A single dose bioavailability study of 3 new formulations of SKI-606 [bosutinib] (500 mg) compared with a reference capsule and an oral solution in healthy adult subjects
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2007
At a glance
- Drugs Bosutinib (Primary)
- Indications Breast cancer; Chronic myeloid leukaemia; Solid tumours
- Focus Pharmacokinetics
- Sponsors Wyeth
- 26 Dec 2007 Status change from in progress to completed.
- 11 Sep 2007 Status changed from initiated to in progress.
- 07 Aug 2007 New trial record.